Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin-angiotensin system inhibitors

Circulation Journal

Volumn 79, Issue 6, 2015, Pages 1307-1314

  Ueda, Tomoya ^a   Kawakami, Rika ^a   Nishida, Taku ^a   Onoue, Kenji ^a   Soeda, Tsunenari ^a   Okayama, Satoshi ^a   Takeda, Yukiji ^a   Watanabe, Makoto ^a   Kawata, Hiroyuki ^a   Uemura, Shiro ^a   Saito, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute decompensated heart failure; Plasma renin activity; Prognosis; Renin angiotensin system blocker

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; RENIN ANGIOTENSIN SYSTEM INHIBITOR; SODIUM; UNCLASSIFIED DRUG; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; RENIN;

ACUTE HEART FAILURE; AGE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; ACUTE DISEASE; BLOOD; CARDIOVASCULAR DISEASE; COMBINATION DRUG THERAPY; COMORBIDITY; DRUG EFFECTS; FEEDBACK SYSTEM; HEART FAILURE; HEART VENTRICLE REMODELING; HOSPITAL READMISSION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; AGED; ALDOSTERONE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOMARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; DRUG THERAPY, COMBINATION; FEEDBACK, PHYSIOLOGICAL; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT READMISSION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; VENTRICULAR REMODELING;

EID: 84930077297     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-1203     Document Type: Article

References (28)

1. Pang PS, Komajda M, Gheorghiade M. The current and future management of acute heart failure syndromes. Eur Heart J 2010; 31: 784 – 793.
2. Bueno H, Ross JS, Wang Y, Chen J, Vidan MT, Normand SL, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA 2010; 303: 2141 – 2147.
3. Sato N, Kajimoto K, Keida T, Mizuno M, Minami Y, Yumino D, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 2013; 77: 944 – 951.
4. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577 – 585.
5. Mann DL, Bristow MR. Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation 2005; 111: 2837 – 2849.
6. Vergaro G, Emdin M, Iervasi A, Zyw L, Gabutti A, Poletti R, et al. Prognostic value of plasma renin activity in heart failure. Am J Cardiol 2011; 108: 246 – 251.
7. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 292 – 299.
8. Opie LH. Mechanisms of cardiac contraction and relaxation. In: Braunwald E, editor. Heart disease, 7th edn. Philadelphia: Saunders, 2004; 457 – 489.
9. Garg R, Yusuf S. Overview of randomized trials of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on AE Inhibitor Trials. JAMA 1995; 273: 1450 – 1456.
10. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759 – 766.
11. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9 – 13.
12. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651 – 1658.
13. Ueda T, Kawakami R, Horii M, Sugawara Y, Matsumoto T, Okada S, et al. High mean corpuscular volume is a new indicator of prognosis in acute decompensated heart failure. Circ J 2013; 77: 2766 – 2771.
14. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22: 6A – 13A.
15. Brunner HR, Sealey JE, Laragh JH. Renin as a risk factor in essential hypertension: More evidence. Am J Med 1973; 55: 295 – 302.
16. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure: Relations to survival and the effects of therapy in V-HeFT II: The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: VI40 – VI48.
17. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. J Am Coll Cardiol 1994; 24: 583 – 591.
18. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819 – 823.
19. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787 – 1847.
20. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147 – e239, doi:10.1016/j.jacc.2013.05.019.
21. JCS Joint Working Group. Guidelines for treatment of acute heart failure (JCS 2011): Digest version. Circ J 2013; 77: 2157 – 2201.
22. van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006; 106: 367 – 372.
23. Schroten NF, Gaillard CA, van Veldhuisen DJ, Szymanski MK, Hillege HL, de Boer RA. New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev 2012; 17: 191 – 201.
24. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709 – 717.
25. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309 – 1321.
26. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11 – 21.
27. Kinouchi K, Ichihara A, Sano M, Sun-Wada GH, Wada Y, KurauchiMito A, et al. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes. Circ Res 2010; 107: 30 – 34.
28. Ando T, Ichihara A. Novel approach to cardiovascular diseases: A promising probability of (pro)renin receptor [(P)RR]. Curr Pharm Des 2014; 20: 2371 – 2376.